Nearly half of the tobacco consumed in the United States is smoked by people with psychiatric illness. In particular, smokers with schizophrenia (SWS) infrequently attempt and attain sustained smoking abstinence and have a 25-year shorter lifespan due to smoking-related illness. SWS are in dire need of effective smoking treatment and are not benefiting from treatments that are currently available. Reducing the nicotine content of cigarettes to non-addicting levels is an innovative strategy that has the potential to significantly reduce tobacco-related morbidity and mortality in this population. In evaluating the potential impact of this strategy, one critical knowledge gap that was identified is whether this strategy would be effective in smokers with serious mental illness, who are more nicotine-dependent than other smokers and who may smoke for self-medication purposes. We are currently studying the acute effects of VLNC cigarettes in SWS, with promising results showing that use of these cigarettes reverses abstinence-induced cigarette craving, withdrawal-related negative mood and usual-brand smoking. Furthermore, SWS rate the subjective effects VLNC cigarettes highly, indicating that such an approach may be acceptable to SWS. However, the effects of prolonged use of VLNC cigarettes on smoking tiehavior, psychiatric symptoms and cognitive functioning in SWS are unknown. This study would be the first to examine whether a regulatory approach of reducing the nicotine content of cigarettes to non-addicting levels is a viable method of reducing smoking in this population. Smokers will be randomized to one of two experimental conditions: 1) very low nicotine content (VLNC) cigarettes with a 0.06 mg nicotine yield (actual dose to be determined by Project 1;n = 40), or 2) normal nicotine content cigarettes (n = 40). Over the 2-week baseline and 6-week treatment phases, subjects will be assessed for patterns of tobacco use, biomarkers of exposure, subjective responses (e.g., satisfaction, craving, withdrawal symptoms), psychiatric symptoms, cognitive performance, smoking cue reactivity and smoking topography. At the end of the 6-week treatment period, subjective and behavioral responses to smoking abstinence will be assessed. The results from this study will describe the possible risks and benefits to smokers with schizophrenia of dramatically reducing the nicotine content of cigarettes. This project will complement and use similar measures as Projects 1 and 2.

Public Health Relevance

; There is an unusually high rate of cigarette smoking and correspondingly high rates of smoking-related morbidity and mortality in smokers with schizophrenia. This project will investigate the effects of 6-week use of very low nicotine content cigarettes on smoking, mood, psychiatric symptoms, cognitive functioning and other measures in smokers with schizophrenia. This information will help to determine whether a public health policy of limiting the nicotine content of cigarettes to very low levels would be effective and safe for these smokers

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54DA031659-02
Application #
8379278
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
2011-09-15
Project End
2016-08-31
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$264,012
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Smith, Tracy T; Cassidy, Rachel N; Tidey, Jennifer W et al. (2017) Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: further results from a multi-site clinical trial. Addiction 112:349-359
Miller, Mollie E; Tidey, Jennifer W; Rohsenow, Damaris J et al. (2017) Electronic Cigarette Expectancies in Smokers with Psychological Distress. Tob Regul Sci 3:108-114
Rupprecht, Laura E; Koopmeiners, Joseph S; Dermody, Sarah S et al. (2017) Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes. Tob Control 26:e43-e48
Murphy, Sharon E; Sipe, Christopher J; Choi, Kwangsoo et al. (2017) Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers. Cancer Epidemiol Biomarkers Prev 26:1093-1099
Mercincavage, Melissa; Wileyto, E Paul; Saddleson, Megan L et al. (2017) Attrition during a randomized controlled trial of reduced nicotine content cigarettes as a proxy for understanding acceptability of nicotine product standards. Addiction 112:1095-1103
Benowitz, Neal L; Donny, Eric C; Hatsukami, Dorothy K (2017) Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game. Addiction 112:6-7
Smith, Tracy T; Rupprecht, Laura E; Sved, Alan F et al. (2016) Characterizing the relationship between increases in the cost of nicotine and decreases in nicotine content in adult male rats: implications for tobacco regulation. Psychopharmacology (Berl) 233:3953-3964
Tidey, Jennifer W; Cassidy, Rachel N; Miller, Mollie E et al. (2016) Behavioral Economic Laboratory Research in Tobacco Regulatory Science. Tob Regul Sci 2:440-451
Dermody, Sarah S; Tidey, Jennifer W; Denlinger, Rachel L et al. (2016) The Impact of Smoking Very Low Nicotine Content Cigarettes on Alcohol Use. Alcohol Clin Exp Res 40:606-15
Rupprecht, Laura E; Smith, Tracy T; Donny, Eric C et al. (2016) Self-Administered Nicotine Suppresses Body Weight Gain Independent of Food Intake in Male Rats. Nicotine Tob Res 18:1869-1876

Showing the most recent 10 out of 41 publications